Clinical Trials Browser

Phase 3 × disitamab vedotin × Breast × Clear all

NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Phase 3 Recruiting

HER2-positive Metastatic Breast Cancer

NCT05904964 2023-06-22

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Phase 3 Recruiting

Breast Neoplasms